Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Bee Venom Phospholipase A2 Inhibitor
AGN-190383 is a potent inhibitor of bee venom phospholipase A2, targeting key enzymes involved in inflammatory processes. It effectively inhibits both hormone-operated and depolarization-dependent calcium mobilization, as well as fMLP-stimulated increases in free cytosolic calcium levels. Due to its ability to modulate calcium signaling and exhibit anti-inflammatory activity, AGN-190383 is valuable for research applications in studying inflammation and calcium-related cellular responses. -
Phospholipase A2 Inhibitors
Ro 23-9358 is a selective inhibitor of secretory phospholipase A2, known for its potent anti-inflammatory properties. By targeting this enzyme, Ro 23-9358 modulates the release of pro-inflammatory lipid mediators, making it a valuable tool in studying inflammatory pathways. Its application is relevant in research focused on inflammatory diseases and the development of therapeutic strategies to mitigate inflammation. -
ASM Inhibitor
ASM-IN-2 is a potent inhibitor of acid sphingomyelinase (ASM), exhibiting an IC50 value of 0.87 μM. This compound plays a crucial role in reducing ceramide levels, which is linked to various antidepressant mechanisms of action. Notably, ASM-IN-2 demonstrates significant antidepressant effects in the chronic unpredictable mild stress (CUMS) mouse model, making it an important tool for research in the development of antidepressant therapies. -
RBBP9 Inhibitor
ML114 is a selective inhibitor of the serine hydrolase RBBP9, exhibiting an IC50 of 0.63 μM against recombinant RBBP9. This compound has been shown to suppress the proliferation of human pluripotent stem cells (hPSCs) by modulating the expression of NFYA and other associated factors, without triggering differentiation. ML114 is valuable for research in cancer pathology, particularly in the study of retinoblastoma. -
sPLA2-IIA Inhibitor
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK, specifically designed to target human Group IIA phospholipase A2 (hGIIA). This compound effectively binds to hGIIA, inhibiting its enzymatic activity and preventing the hydrolysis of glycerophospholipids. This inhibition leads to decreased production of free fatty acids, such as arachidonic acid, making it a valuable tool for studying inflammatory processes and lipid metabolism in various biological models. Its application is particularly relevant in research aimed at understanding related pathophysiological conditions. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-6 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with an exceptional pIC50 of 10.0 against recombinant human Lp-PLA2. This tetracyclic pyrimidinone compound is primarily utilized in research focusing on neurodegenerative diseases, where its biological activity may contribute to a deeper understanding of disease mechanisms and the development of therapeutic strategies. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-12 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound has shown potential in the study of neurodegenerative diseases such as Alzheimer's disease, as well as ocular conditions like glaucoma and age-related macular degeneration. Additionally, Lp-PLA2-IN-12 is relevant for research on cardiovascular diseases, including atherosclerosis, by modulating inflammatory processes associated with these conditions. -
Phospholipase A2 Inhibitor
Folipastatin is a potent inhibitor of phospholipase A2, demonstrating an IC50 value of 39 μM. This novel depsidone compound, derived from Aspergillus unguis, exhibits significant biological activity, making it a valuable tool for studies related to phospholipid metabolism and inflammatory processes. Its application extends to research on lipid signaling pathways and related cellular mechanisms. -
SMS2 Inhibitor
SMS2-IN-3 is a potent and selective inhibitor of sphingomyelin synthase 2 (SMS2) with an IC50 of 2.2 nM. This compound significantly reduces hepatic sphingomyelin (22:0) levels, making it a valuable tool for research into sphingolipid metabolism and its implications in various metabolic disorders. SMS2-IN-3 is applicable in studies exploring the role of sphingolipids in health and disease. -
Sphingomyelinase Inhibitor
SM (d18:1/15:0) is an inhibitor of sphingomyelinase, a crucial enzyme involved in sphingolipid metabolism. This compound demonstrates potential in the study of neurodegenerative diseases such as Alzheimer's and metabolic syndrome. Its mechanism of action makes it a valuable tool for investigating the roles of sphingolipids in various cellular processes and disease states. -
HSF-PLA2 Inhibitor
Luffariellolide is a potent inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2), with an IC50 value of 5 μM. This compound has demonstrated significant anti-inflammatory activity, evidenced by its ability to effectively inhibit phorbol ester (PMA)-induced ear edema, with an ED50 of 50 μg/ear. Luffariellolide is a valuable tool for research applications focused on inflammation and lipid metabolism. -
PLA2 Inhibitor
MJ33-OH is a metabolite of MJ33, functioning as a specific, competitive, and reversible inhibitor of phospholipase A2 (PLA2). This compound effectively inhibits the activity of calcium-independent phospholipase A2 (iPLA2), particularly in the context of Prdx6 regulation. MJ33-OH is valuable for research applications focused on studying PLA2-related pathways and its implications in various biochemical processes. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-15 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound exhibits potent inhibitory activity, making it valuable for investigating the role of Lp-PLA2 in various biological processes. It is particularly relevant in Alzheimer's disease research and other studies related to inflammation and lipid metabolism. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-14 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with a pIC50 of 8.4 against recombinant human Lp-PLA2. This compound demonstrates significant potential in the study of neurodegenerative diseases, such as Alzheimer’s disease, glaucoma, and age-related macular degeneration, as well as cardiovascular conditions, including atherosclerosis. Lp-PLA2-IN-14 serves as a useful tool for researchers investigating the role of Lp-PLA2 in these pathologies. -
Sphingomyelinase Inhibitor
Brinazarone is a potent inhibitor of acid lysosomal sphingomyelinase, leading to the accumulation of sphingolipids within cells and resulting in cellular lipidosis. This compound enhances the cytotoxicity of specific immunotherapeutic agents, such as anti-Thy 1.2 AT15E RTA-IT on T2 cells and anti-CD5 T101 on CEM cells. Brinazarone is valuable for research applications involving sphingolipid metabolism and cancer immunotherapy studies. -
Lp-PLA2 Inhibitor
SB-435495 ditartrate is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), demonstrating a remarkable IC50 of 0.06 nM. This compound functions as a reversible, non-covalent inhibitor and is suitable for oral administration. Its inhibition of Lp-PLA2 has significant implications for research in cardiovascular diseases and inflammatory processes, making it a valuable tool for investigating pathophysiological roles and therapeutic interventions in related conditions. -
sPLA2 Inhibitor
Me-Indoxam is a potent inhibitor of secreted phospholipase A2 (sPLA2) that exhibits cell-impermeable characteristics. This compound effectively binds to the active site of sPLA2, disrupting its enzymatic function. Me-Indoxam is valuable in research applications focused on inflammation, cell signaling, and lipid metabolism, providing insights into the role of sPLA2 in various biological processes. -
PTDSS1 Inhibitor
DS07551382 is a selective inhibitor of phosphatidylserine synthase 1 (PTDSS1), effectively disrupting the intracellular synthesis of phosphatidylserine. This compound demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology. Its ability to modulate phosphatidylserine levels can provide insights into various signaling pathways involved in tumor progression and may aid in the development of novel therapeutic strategies. -
cPLA2α Inhibitor Derivative
cPLA2α-IN-derivative 1 is an inactive alcohol derivative designed to target cytosolic phospholipase A2α (cPLA2α). Although it exhibits no inhibition activity, it serves as a useful reference compound in structure-activity relationship studies. This reagent can be utilized in research focused on elucidating the role of cPLA2α in lipid metabolism and inflammatory responses. -
Phospholipase Inhibitor
A4333 is a biotinylated inhibitor of Phospholipase D1 (PLD1), selectively targeting this enzyme while sparing PLD2. This compound is significant in cancer research, demonstrating potent antitumor activity. Its specificity for PLD1 makes A4333 a valuable tool for elucidating the role of phospholipase signaling in tumor biology and potential therapeutic applications. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-16 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), a key enzyme implicated in inflammatory processes. This compound demonstrates potent inhibition of Lp-PLA2 activity, making it a valuable tool for investigating its role in neurodegenerative diseases, such as Alzheimer's disease. Its application in biochemical research supports studies focused on inflammation-related pathways and potential therapeutic targets. -
PLA2 Inhibitor
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA) functions primarily as a phospholipase A2 (PLA2) inhibitor, exhibiting selective inhibition against both P388D1 cell PLA2 (IC50 = 16 µM) and snake venom PLA2 (IC50 = 14 µM). As a non-metabolizable analog of arachidonic acid, DEDA serves as a valuable tool in biochemical studies related to PLA2 activity. Its unique properties make it suitable for researching inflammatory processes and signal transduction pathways modulated by phospholipid metabolism. -
Phospholipase A2 Inhibitor
Cinatrin A is a potent inhibitor of phospholipase A2, an enzyme involved in the hydrolysis of phospholipids, leading to the generation of inflammatory mediators. This compound exhibits significant anti-inflammatory properties and is valuable for research applications focused on inflammation, pain modulation, and related signaling pathways. Its mechanism of action makes it a valuable tool for studying phospholipid metabolism and the implications of phospholipase A2 in various diseases. -
Phospholipase Inhibitor
(R)-N-(1-Hydroxypropan-2-yl)palmitamide serves as a substrate analog inhibitor targeting phospholipase A2. This compound exhibits significant inhibition of enzymatic activity, making it valuable for research related to inflammatory processes and cellular signaling. Its application in studying phospholipid metabolism and lipid mediator synthesis further enhances its utility in biochemical and pharmacological investigations. -
cPLA2α Inhibitor
AVX001 is a selective inhibitor of cytosolic phospholipase A2 alpha (cPLA2α). This compound is instrumental in the study of inflammatory processes, particularly in conditions such as psoriasis. AVX001 modulates the release of arachidonic acid, thereby influencing eicosanoid signaling pathways, and provides valuable insights into therapeutic strategies targeting inflammatory disorders. -
nSMase Inhibitor
Chlorogentisylquinone is an inhibitor of neutral sphingomyelinase (nSMase), demonstrating an IC50 value of 1.2 μM against rat meningeal cells and 7.6 μM in P388 leukemia cells. This compound is derived from the strain FOM-8108 and serves as a valuable tool for studying the role of nSMase in cellular processes. Its biological activity makes it suitable for applications in neurobiology and cancer research. -
PLA2 Inhibitor
Cinatrin C2 is a potent inhibitor of phospholipase A2 (PLA2) with an IC50 of 800 μM. This compound, sourced from Circinotrichum falcatisporum RF-641, is valuable for studying PLA2's role in various biological processes. It is applicable in research areas related to inflammation, pain mechanisms, and cellular signaling pathways. -
ASM Inhibitor
ASM-IN-3 is a selective inhibitor of acid sphingomyelinase (ASM) with a reported IC50 of 3.37 μM for human ASM. This compound demonstrates the ability to penetrate the blood-brain barrier and has been shown to enhance neurogenesis in the hippocampus, alleviating depression-like behaviors in Reserpine-induced rat models. ASM-IN-3 serves as a valuable tool for research in neurobiology and the treatment of mood disorders. -
PLA2 Inhibitor
Cinatrin C3 is a selective phospholipase A2 (PLA2) inhibitor, exhibiting an IC50 value of 70 μM. This compound is derived from the marine fungus Circinotrichum falcatisporum RF-641. Cinatrin C3 is utilized in research to explore the functional roles of PLA2 in various biological processes, including inflammation and cellular signaling pathways. Its inhibitory properties make it a valuable tool for studying the mechanistic functions of PLA2 in pathophysiological contexts. -
PLA2 Inhibitor
Cinatrin C1 is a selective phospholipase A2 (PLA2) inhibitor derived from the fungus Circinotrichum falcatisporum RF-641. This compound exhibits significant biological activity by modulating lipid metabolism and inflammatory processes. Cinatrin C1 serves as a valuable tool in biochemical research focused on elucidating the role of PLA2 in various physiological and pathological conditions. -
FabZ Inhibitor
HpFabZ-IN-1 is an inhibitor of the FabZ enzyme, which plays a crucial role in the fatty acid synthesis pathway of Helicobacter pylori. With an IC50 value of 39.8 µM, this compound is primarily utilized in research investigating fatty acid biosynthesis and related metabolic pathways in H. pylori. Although it does not exhibit antibacterial activity, HpFabZ-IN-1 serves as an important tool for studying the molecular mechanisms underlying this pathogenic bacterium. -
PLD Inhibitor
ARF1 (2-17) is a selective inhibitor of phospholipase D (PLD) and phospholipase C-β (PLC-β), targeting both ARF-dependent and ARF-independent signaling pathways. This compound effectively inhibits GTP-γ-S-stimulated PLD activity, thereby playing a crucial role in modulating exocytosis and related cellular processes. Its application in research includes studying lipid signaling and the regulation of membrane traffic in cellular models. -
Phospholipase A2 Inhibitor
Cinatrin B is a potent inhibitor of phospholipase A2, an enzyme involved in the hydrolysis of phospholipids, leading to the release of arachidonic acid and the subsequent production of inflammatory mediators. This compound demonstrates significant biological activity in modulating inflammatory responses and has potential applications in research related to inflammation and related diseases. Its ability to selectively inhibit phospholipase A2 makes Cinatrin B a valuable tool for studying lipid metabolism and signaling pathways in various biological systems. -
Phospholipase A2 Inhibitor
Ro 31-4639 is a potent inhibitor of phospholipase A2, displaying an IC50 of 1.5 μM. This compound is valuable for studying the role of phospholipase A2 in inflammatory processes and membrane biochemistry. Its inhibitory activity makes it a critical tool in investigating pathways related to lipid metabolism and the modulation of arachidonic acid release. -
cPLA2 Inhibitor
AK106-001616 is a selective inhibitor of cytosolic phospholipase A2 (cPLA2), exhibiting a potent inhibition with an IC50 of 3.8 nmol/L. This compound effectively reduces the synthesis of pro-inflammatory mediators, including prostaglandins E2 and leukotrienes B4, in stimulated cells. AK106-001616 is valuable for research into inflammatory diseases, neuropathic pain, and pulmonary fibrosis, providing insights into the modulation of inflammatory pathways. -
Phospholipase C Inhibitor
Hispidospermidin is a selective inhibitor of phospholipase C, a key enzyme involved in various signal transduction pathways. This compound exhibits significant biological activity by modulating intracellular calcium signaling and inositol phosphate metabolism. Its potential applications in research include studying cellular signaling mechanisms and investigating diseases related to dysregulated phospholipase C activity. -
ASM Inhibitor
ARC39 is a selective inhibitor of acid sphingomyelinase (ASM), a key enzyme involved in sphingolipid metabolism. By inhibiting ASM, ARC39 modulates sphingolipid levels, which play critical roles in cellular signaling and stress responses. Its biological activity makes it a valuable tool for research related to neurodegenerative diseases, cancer, and inflammation, facilitating the exploration of sphingolipid-related pathways in various cellular contexts. -
N-SMase 2 Inhibitor
DPTIP hydrochloride is a selective inhibitor of neutral sphingomyelinase 2 (N-SMase 2), exhibiting an IC50 of 30 nM. This compound is known for its ability to penetrate the blood-brain barrier, making it a valuable tool for studying exosome-mediated cellular processes. Research applications include investigations into neurodegenerative diseases and the role of sphingosine metabolism in cellular signaling pathways. -
nSMase Inhibitor
Sphingolactone-24 is a selective and irreversible inhibitor of neutral sphingomyelinase (nSMase). This compound is significant in biological research due to its ability to modulate sphingolipid metabolism, which plays a critical role in various cellular processes. Sphingolactone-24 is particularly useful in studies related to acute lung injury, enabling researchers to explore therapeutic interventions in respiratory conditions associated with nSMase activity. -
Group IVA Cytosolic Phospholipase A2 Inhibitor
GK470 is a potent inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. This compound exhibits significant anti-inflammatory activity by inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes, with an IC50 of 0.6 μM. GK470 demonstrates comparable anti-inflammatory effects to conventional therapies in models of arthritis and effectively reduces plasma PGE2 levels, making it a valuable tool for researching inflammatory pathways and potential therapeutic interventions.
